TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01395953

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buspirone
Description: Children with Autism Spectrum Disorders will receive buspirone or matched placebo. Buspirone will be titrated to the maximum daily dose during the first four weeks of the trial (dose titration phase). Week 4 onwards subjects will be maintained on maximum achieved dose till the end of the trial (dose maintenance phase). During the titration phase total dose of buspirone will be increased at each visit by 5mg and on the 4th day after each visit by 5mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Children with Autism Spectrum Disorders will receive buspirone or matched placebo. Buspirone will be titrated to the maximum daily dose during the first four weeks of the trial (dose titration phase). Week 4 onwards subjects will be maintained on maximum achieved dose till the end of the trial (dose maintenance phase). During the titration phase total dose of buspirone will be increased at each visit by 5mg and on the 4th day after each visit by 5mg.
Study: NCT01400113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asenapine
Description: Asenapine Sublingual Tablet 10mg, single-dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Sublingual Tablet, single-dose
Study: NCT02934295

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Determination of Anti-Rubella Antibody, E1
Study: NCT01041781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed disodium
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pemetrexed disodium
Description: Given IV

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Given orally
Study: NCT05043233

Intervention type: DRUG
Intervention: Methimazole(MMI)
Description: Methimazole is a widely used antithyroid drug and is often used in the treatment of Graves' disease hyperthyroidism
Study: NCT01508936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reslizumab
Description: Reslizumab administered at a dosage of 3.0 mg/kg by intravenous (iv) infusion by qualified study personnel every 4 weeks for 16 weeks (for a total of 4 doses).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo administered by intravenous (iv) infusion by qualified study personnel every 4 weeks for 16 weeks (for a total of 4 doses).
Study: NCT03279679

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: costoclavicular infraclavicular block
Description: Infraclavicular brachial plexus block will be performed through new costoclavicular space approach under realtime ultrasound guidance with 0.5% ropivacaine

Intervention type: PROCEDURE
Group type: OTHER
Intervention: paracoracoid infraclavicular block
Description: Infraclavicular brachial plexus block will be performed through traditional paracoracoid approach under realtime ultrasound guidance with 0.5% ropivacaine

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: All the nerve blocks will be performed under realtime ultrasound guidance

Intervention type: DEVICE
Group type: OTHER
Intervention: Ultrasound
Description: All the nerve blocks will be performed under realtime ultrasound guidance

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: 0.5% ropivacaine will be used for the brachial plexus block in both groups.

Intervention type: DRUG
Group type: OTHER
Intervention: Ropivacaine
Description: 0.5% ropivacaine will be used for the brachial plexus block in both groups.
Study: NCT02508961

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: web-based physio exercise programme

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: web-based physio exercise programme
Study: NCT05409677

Intervention type: OTHER
Intervention: This was a retrospective study with no intervention other than normal treatment
Description: This was a retrospective study with no intervention other than normal treatment
Study: NCT02407379

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PAPD+SRP
Description: Photoablation of the gingival epithelium was performed with at 810 nm diode laser (1 W output power, continuous wave mode, 66.7 J/cm2, a 0.6 mm optical fiber). SRP was performed using curettes. The periodontal tissues and the dental root were rinsed with the photosensitizer agent methylene blue (0.3% w/v in water). After 5 min., the treated areas were irradiated with at 635 nm diode laser (100 mW output power, continuous wave mode, 0.6 mm optic fiber). The photodynamic treatment was repeated once weekly until normalization of the cytodiagnostic parameters (range: 4-10 applications).

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham-laser +SRP
Description: Sham-treatment was similar to the previously described treatment but with switched off laser, followed by scaling and root planing
Study: NCT04807114

Intervention type: DRUG
Intervention: Immune checkpoint inhibitor
Description: Standard-of-care treatment for st.IV NSCLC (no driver mutation, PD-L1 \> 50%)

Intervention type: DRUG
Intervention: Chemotherapy + Immune checkpoint inhibitor
Description: Standard-of-care treatment for st.IV NSCLC (no driver mutation, PD-L1 \< 50%)
Study: NCT01625156

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivantinib
Description: Given PO
Study: NCT00194740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 60 mg/m2, IV, day 1 of each 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: 27.5 mg/m2, IV, days 8 \& 15 of each 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: 5 µg/kg/day s.c., to be administered days 2-21 of each cycle.
Study: NCT02018146

Intervention type: OTHER
Group type: OTHER
Intervention: Mask then nasopharyngeal
Description: Patients will be randomly assigned to Mask ventilation followed by naso-pharyngeal ventilation

Intervention type: OTHER
Group type: OTHER
Intervention: Nasopharyngeal then mask
Description: Patients will be randomly assigned to naso-pharyngeal ventilation followed by mask ventilation.
Study: NCT00195494

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Group 1b: Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 1 then Etanercept 50 mg SC injections weekly + Placebo weekly for Period 2~Group 2a: Oral Methotrexate weekly + Placebo for Period 1, then Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 2
Study: NCT06428994

Intervention type: RADIATION
Intervention: Radiotherapy
Description: Post-operative radiotherapy for head and neck cancer
Study: NCT03035916

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transversus abdominis plane block
Description: Participants in this group receive ultrasound-guided TAP block under bilateral costal margin with multiple injections of 40ml 0.375% ropivacaine after the induction of general anesthesia, 30 minutes later the surgery will be started.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Epidural anesthesia
Description: Participants in the Epidural group receive a epidural block (T8-9) with 2 mL of 1.6% lidocaine as a test dose before induction. After a successful placement of epidural catheter, the block then is established with 5 mL of 0.375% ropivacaine and continous infusion of 0.375% ropivacaine(5 mL/h) during the surgery.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control
Description: The Control group receives standard IV-inhaled general anesthesia.
Study: NCT02636803

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxfendazole
Description: group receives a single dose of oxfendazole at 6 or 30 mg/kg or three 6 mg/kg doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxfendazole
Description: group receives a single dose of oxfendazole at 6 or 30 mg/kg or three 6 mg/kg doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxfendazole
Description: group receives a single dose of oxfendazole at 6 or 30 mg/kg or three 6 mg/kg doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: albendazole
Description: group receives one 400 mg dose of albendazole
Study: NCT02895139

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Additive Manufactured Orthotic Device
Description: The 3D foot scan data will be used to generate a 3D model of the foot orthotic which will then be adapted to be suitable for solid printing. The final model will be saved in .stl format for use in the printing software. The additive manufactured orthotic insoles and all features or additions will be produced in a single build from additive materials matched for hardness to medium density EVA. Post production the orthotic will be cleaned to remove support material and a top cover will be attached to the final additive manufactured orthotic insole.

Intervention type: DEVICE
Group type: OTHER
Intervention: Moulded orthotic
Description: The foam impression box and prescription will be sent to an external company for production of the handmade moulded orthotics. Handmade moulded orthotics will be produced by heating and wrapping medium density Ethylene-vinyl acetate (EVA) around plaster casts of the impression boxes. The orthotic insoles may be manually adapted to meet the requirements of the prescription, this could include cut out sections designed to offload regions of the foot or the addition of features such as metatarsal bars which provide varied support. Features and additions will be added in post manually by cutting and gluing onto the moulded orthotic insole. A top cover will be attached to the final moulded orthotic insole.

Intervention type: DEVICE
Group type: OTHER
Intervention: Milled orthotic
Description: The 3D foot scan data will be used to generate a 3D model of the foot orthotic. This will then be saved in .pan format for use in a CNC milling software. Orthotics and all features will be milled in a single mill from a block of medium density EVA. Post milling the orthotics will be cleaned. The orthotic insoles may be manually adapted to meet the requirements of the prescription, this could include cut out sections designed to offload regions of the foot or the addition of features such as metatarsal bars which provide varied support. Features and additions will be added in post manually by cutting and gluing onto the milled orthotic insole. A top cover will be attached to the final milled orthotic insole.
Study: NCT04498598

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A/Z Supraglottic airway
Description: Patient receive supraglottic airway for general anesthesia which can be converted to endotracheal ventilation reversibly
Study: NCT02006056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: Patients will take Ondissolve (8mg) on the day of the radiation treatment at least one hour prior to treatment and repeat approximately 6-8 hours later in the day (bid). For patients who are being treated with 20Gy in 5 fractions, or 30 Gy in 10 fractions, this group will take Ondissolve twice (bid) on each day of treatment, at least 1 hour prior to treatment and also on weekends or holidays in between treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: Patients will take Ondissolve (8mg) on the day of the radiation treatment at least one hour prior to treatment and repeat approximately 6-8 hours later in the day (bid). For patients who are being treated with 20Gy in 5 fractions, or 30 Gy in 10 fractions, this group will take Ondissolve twice (bid) on each day of treatment, at least 1 hour prior to treatment and also on weekends or holidays in between treatment.
Study: NCT02577627

Intervention type: DEVICE
Intervention: PrediCare

Intervention type: DEVICE
Intervention: PrediCare
Study: NCT03419130

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Radiation Therapy
Description: Undergo hypofractionated RT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo conventionally fractionated RT
Study: NCT03851978

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pharmacist Vaccine Education
Description: When an eligible patient presents to the pharmacy for prescription pick up or drop off, the pop-up note will notify the technician to get a pharmacist for education. The pharmacist will educate the patient on the vaccine and then recommend that the patient receives the vaccine.
Study: NCT03887429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SXC-2023
Description: SXC-2023 oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SXC-2023
Description: SXC-2023 oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SXC-2023
Description: SXC-2023 oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SXC-2023
Description: SXC-2023 oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: Matching Placebo oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: Matching Placebo oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: Matching Placebo oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: Matching Placebo oral capsules
Study: NCT02585687

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: liver Perfusion MRI
Study: NCT02584959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C1 esterase inhibitor [human] liquid
Description: C1 Esterase Inhibitor \[Human\] Liquid administered Subcutaneously as specified on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C1 esterase inhibitor [human] liquid
Description: C1 Esterase Inhibitor \[Human\] Liquid administered Subcutaneously as specified on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C1 esterase inhibitor [human] liquid
Description: C1 Esterase Inhibitor \[Human\] Liquid administered Subcutaneously as specified on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT01250353

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pterygium surgery
Description: pterygium was removed surgically

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pterygium surgery
Description: pterygium was removed surgically
Study: NCT00987597

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Technique of in-vivo exposure (cigarette) and mental image exposure (craving)
Description: Nicotine replacement

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: conventional follow-up
Description: nicotinic substitutes
Study: NCT03986229

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Evaluate the variation in the travel speed of the center of pressure with and without compression garments.
Description: Each evaluation will be done according to the following protocol:~* Evaluation of the pain~* Berg test~* One test per condition starting with open eyes~* Standardized instructions:~* Break about 15 minutes (wash-out) between each test.~* Both conditions will be tested on the same day.~* Evaluation in an environment free from visual and audible interference.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Evaluate the variation in the travel speed of the center of pressure with and without compression garments.
Description: Each evaluation will be done according to the following protocol:~* Evaluation of the pain~* Berg test~* One test per condition starting with open eyes~* Standardized instructions:~* Break about 15 minutes (wash-out) between each test.~* Both conditions will be tested on the same day.~* Evaluation in an environment free from visual and audible interference.
Study: NCT03131700

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RPH001
Description: Avastin® has been approved for treatment of various cancers in many countries of the world including the USA, EU countries, and Turkey. In Turkey, Avastin® is approved with a different trade name, Altuzan®, for treatment of metastatic colorectal cancer.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Avastin®
Description: R-Pharm created a biological analog of Avastin®, RPH-001. RPH-001 and Avastin® have similar physicochemical properties, pharmacokinetic profile and affinity to human vascular endothelial growth factor, similar toxicity and efficacy confirmed by preclinical study results.
Study: NCT01267825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT-guided corticosteroid+ bupivicaine
Description: CT-guided corticosteroid+ bupivicaine Also get standard medical care

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard medical care
Description: Naproxen + Oxycodone/ Acetaminophen
Study: NCT04154514

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A functional electrical stimulation device for post-stroke rehabilitation
Description: Most of the FDA-approved commercial FES devices deliver therapy that targets specific kinematic impairment in the step cycle (e.g., foot drop). Our device will be unique in that it can stimulate many muscles around multiple joints for a more comprehensive and naturalistic restoration of lower-limb motor functions.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A functional electrical stimulation device for post-stroke rehabilitation
Description: Most of the FDA-approved commercial FES devices deliver therapy that targets specific kinematic impairment in the step cycle (e.g., foot drop). Our device will be unique in that it can stimulate many muscles around multiple joints for a more comprehensive and naturalistic restoration of lower-limb motor functions.
Study: NCT04256213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab and Ipilimumab
Description: Nivolumab, IV D1C1 and D15C1 (before RT-CT) at 3 mg/kg Every 28 days at 480 mg during 6 months after RT-CT~Ipilimumab, 1 mg/kg, IV D1C1 (before RT-CT)
Study: NCT01869569

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: At the 4-week dose-titration phase, will receive one capsule of pregabalin (75 mg) twice daily from Day 1 to Day 7, and two capsules of pregabalin (150 mg) twice daily from Day 8 to Day 14. From Day 15 to Day 28, patients will perform dosage adjustments based on the pain relief and tolerability. At maintenance phase, patients will take the optimized dosage of pregabalin.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: At the 4-week dose-titration phase, will receive one capsule of placebo twice daily from Day 1 to Day 7, and two capsules of placebo twice daily from Day 8 to Day 14. From Day 15 to Day 28, patients will perform dosage adjustments based on the pain relief and tolerability. At maintenance phase, patients will take the optimized dosage of placebo.
Study: NCT04052360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenerimod
Description: A single oral dose of 4 mg cenerimod will be administered as a film-coated tablet in the morning of Day 1 under fasted conditions.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: A single oral dose of matching placebo will be administered as a film-coated tablet in the morning of Day 1 under fasted conditions.
Study: NCT04150705

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FDG PET/MRI
Description: -All patients will undergo a simultaneous list mode PET and MR acquisition beginning 55-65 minutes after administration of FDG according to a standard weight-based scale.
Study: NCT04333225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Weekly treatment in individuals at high risk
Study: NCT04786665

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strawberry
Description: Freeze dried strawberry powder

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: Comparative placebo powder
Study: NCT02958332

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: video game program
Description: Participants will use the Wii console and the Wii balance board, to play different video games which imply shoulder movements. They will receive 5 individual sessions of 30 minutes.
Study: NCT02472626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6,8-Bis(benzylthio)octanoic Acid
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin Hydrochloride
Description: Given IV
Study: NCT01807728

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group 1 Training Program
Description: Up to four group classes which will involve peer interaction, hands on training activities, and interaction with group leader(s).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group 2 Training Program
Description: Two group classes which will involve peer interaction, hands on training activities, and interaction with group leader(s).
Study: NCT03383094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg IV infusion every 3 weeks x 20 cycles

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation therapy
Description: 70 Gy in 33-35 fractions

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: 70 Gy in 33-35 fractions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: 100 mg/m2 Weeks 1, 4, and 7.